# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 33738
- Completion tokens: 14603
- Reasoning tokens: 0
- Total tokens: 48341
- API requests reported: 3
- Elapsed seconds: 245.929
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
# Multidimensional Interpretation of Ulcerative Colitis Transcriptomic Data

## 1. Overall Biological Interpretation

The transcriptomic profile of colonic mucosal tissue from ulcerative colitis (UC) patients versus healthy controls reveals a coherent disease-state signature centered on **innate immune activation, epithelial stress responses, and metabolic dysregulation** (100 selected genes; 40 upregulated, 60 downregulated; all FDR ≤ 3.76e-10).

The most striking pattern is a coordinated upregulation of **neutrophil-associated and antimicrobial defense programs**: S100A8 (log2FC=3.80), S100P (log2FC=1.77), LCN2 (log2FC=2.67), CHI3L1 (log2FC=4.59), DUOX2 (log2FC=4.67), DUOXA2 (log2FC=2.89), and PI3 (log2FC=2.21). These are accompanied by strong chemokine signals (CXCL1 log2FC=3.46, CXCL2 log2FC=2.80, CXCL3 log2FC=2.33) and matrix remodeling genes (MMP3 log2FC=4.64, TNC log2FC=2.58, TIMP1 log2FC=1.97), consistent with active mucosal inflammation and tissue restructuring.

Simultaneously, there is a marked **downregulation of differentiated colonic epithelial functions**: water/fluid transport (AQP7 log2FC=-2.32, AQP8 log2FC=-4.42), bile acid transport (SLC51A log2FC=-3.71, ABCB11 log2FC=-1.15), xenobiotic metabolism (CYP2B6 log2FC=-2.78, CYP2B7P log2FC=-2.72, UGT2A3 log2FC=-2.68), and ketogenesis/lipid metabolism (HMGCS2 log2FC=-3.45, ACSF2 log2FC=-1.93). This bidirectional pattern—immune activation up, differentiated epithelial function down—is a hallmark of inflamed UC mucosa.

The overall picture is one of **epithelial dedifferentiation and metabolic reprogramming** occurring in parallel with **innate immune infiltration and activation**, with a notable **adaptive immune component** (CTLA4 log2FC=2.62, immunoglobulin locus log2FC=1.89, DAPP1 log2FC=2.20).

---

## 2. Core Biological Programs

### Program 1: Neutrophil Recruitment and Innate Antimicrobial Defense
- **Direction**: Upregulated in UC
- **Supporting genes**: S100A8, S100P, LCN2, CHI3L1, DUOX2, DUOXA2, PI3, CXCL1, CXCL2, CXCL3, VNN1
- **Standardized pathway**: KEGG IL-17 signaling pathway; GO: antimicrobial humoral response
- **Rationale**: S100A8 (calprotectin subunit) and LCN2 (lipocalin-2) are canonical neutrophil/innate defense markers. DUOX2/DUOXA2 encode the dual oxidase system generating reactive oxygen species for mucosal host defense. The CXCL1/CXCL2/CXCL3 cluster are potent neutrophil chemoattractants acting through CXCR2 (STRING network evidence shows CXCL1, CXCL2, CXCL3 connected to CXCR2). PI3 (elafin) is a protease inhibitor induced during epithelial stress. CHI3L1 (YKL-40) is a chitinase-like protein associated with inflammation and tissue remodeling.
- **Evidence strength**: Strong—multiple independent genes with extremely high significance (FDR from 4.4e-26 to 4.4e-11); pathway co-membership in IL-17 signaling; coherent biological direction.
- **Limitations**: These genes are also expressed in other inflammatory conditions; not UC-specific per se.

### Program 2: Epithelial Differentiation Loss and Metabolic Reprogramming
- **Direction**: Downregulated in UC
- **Supporting genes**: AQP7, AQP8, SLC51A, ABCB11, HMGCS2, G6PC, CYP2B6, CYP2B7P, UGT2A3, ABCG2, SLC16A1, SLC23A1, SLC23A3
- **Standardized pathway**: KEGG Bile secretion; GO: water transport (GO:0006833), fluid transport (GO:0042044)
- **Rationale**: The coordinated loss of water channels (AQP7, AQP8), bile acid transporters (SLC51A, ABCB11), ketogenic enzyme (HMGCS2), gluconeogenic enzyme (G6PC), and xenobiotic metabolism enzymes (CYP2B6, UGT2A3) indicates loss of mature colonocyte identity. STRING evidence shows AQP7–AQP8 interaction (confidence 0.892) and SLC51A–SLC51B interaction (confidence 0.999), supporting a coordinated transport module.
- **Evidence strength**: Strong—many independent genes, all highly significant (FDR from 4.0e-20 to 1.1e-10), consistent direction.
- **Limitations**: This pattern could partly reflect epithelial cell loss/damage rather than pure transcriptional reprogramming; cell-composition effects need consideration.

### Program 3: Tissue Remodeling and Extracellular Matrix Turnover
- **Direction**: Upregulated in UC
- **Supporting genes**: MMP3, TIMP1, TNC, TGM2, PDPN, SERPINB5, CDH3, PRRX1, FILIP1L
- **Standardized pathway**: KEGG Rheumatoid arthritis (ECM-receptor interaction); Reactome: Extracellular matrix organization
- **Rationale**: MMP3 (log2FC=4.64) is a major matrix metalloproteinase degrading extracellular matrix; TIMP1 is its natural inhibitor (co-expressed, suggesting active remodeling balance). TNC (tenascin-C) is an ECM glycoprotein induced during inflammation and wound healing. TGM2 (tissue transglutaminase) cross-links ECM proteins. PDPN (podoplanin) marks remodeling/lymphatic endothelium. STRING evidence connects FREM2, TGM2, TNC to ITGB1 (integrin beta-1), suggesting integrin-mediated ECM signaling.
- **Evidence strength**: Moderate-strong—multiple independent genes with high significance; coherent functional theme.
- **Limitations**: ECM remodeling is a downstream consequence of inflammation; not a primary driver per se.

### Program 4: Adaptive Immune and Regulatory Signaling
- **Direction**: Upregulated in UC
- **Supporting genes**: CTLA4, DAPP1, IL1RN, SOCS3, IRAK3, IFI16, CD55, immunoglobulin locus (IGHV4-31|IGHM|IGHG1)
- **Standardized pathway**: Reactome: Immune System; GO: regulation of inflammatory response
- **Rationale**: CTLA4 (log2FC=2.62) is a key immune checkpoint regulating T-cell responses. IL1RN (IL-1 receptor antagonist, log2FC=2.88) is an endogenous anti-inflammatory cytokine induced during inflammation. SOCS3 (log2FC=2.79) and IRAK3 (log2FC=1.78) are negative regulators of cytokine signaling. DAPP1 (log2FC=2.20) is a B-cell adaptor. The immunoglobulin heavy chain cluster upregulation reflects plasma cell infiltration, a known feature of UC.
- **Evidence strength**: Moderate—multiple genes with high significance; coherent regulatory theme; but these are mixed pro- and anti-inflammatory signals.
- **Limitations**: The direction is ambiguous—some genes (CTLA4, IL1RN, SOCS3, IRAK3) are negative regulators, suggesting compensatory anti-inflammatory responses rather than a single pro-inflammatory program.

### Program 5: Epithelial Stress Response and Barrier Dysfunction
- **Direction**: Mixed (mostly upregulated stress markers, downregulated barrier genes)
- **Supporting genes**: TRIM29, SLC6A14, ARNTL2, PRRX1, REG4, TGM2, CD55, DEFB1 (down), MEP1B (down)
- **Standardized pathway**: GO: response to stress; Reactome: Innate Immune System
- **Rationale**: TRIM29 (log2FC=2.83) is an epithelial stress-induced E3 ligase implicated in DNA damage response. SLC6A14 (log2FC=4.85) is an amino acid transporter upregulated in inflamed epithelium. ARNTL2 (log2FC=1.78) is a circadian gene induced under hypoxic/inflammatory stress. REG4 (log2FC=2.05) is a regenerating islet-derived protein marking regenerative epithelium. The loss of DEFB1 (beta-defensin-1, log2FC=-2.31) and MEP1B (meprin A metalloprotease, log2FC=-2.99) suggests compromised constitutive antimicrobial barrier function.
- **Evidence strength**: Moderate—multiple genes with high significance but heterogeneous functions.
- **Limitations**: This program overlaps with Programs 1–3; separating a distinct "stress response" from immune activation and metabolic loss is partly artificial.

---

## 3. Key Genes and Interaction Modules

### Module 1: Neutrophil Chemokine Axis (CXCL1/CXCL2/CXCL3 → CXCR2)
- **Statistics**: CXCL1 log2FC=3.46; CXCL2 log2FC=2.80; CXCL3 log2FC=2.33; all FDR < 2.6e-11
- **Role**: Central to neutrophil recruitment in UC mucosa
- **Interaction type**: Pathway co-membership and ligand-receptor relationship (STRING network evidence links all three to CXCR2); the three chemokines share the CXCR2 receptor and are co-induced by IL-17/NF-κB signaling
- **Evidence**: Direct input statistics; STRING network evidence; KEGG IL-17 pathway co-membership. Not direct physical interaction—this is a ligand-receptor signaling relationship.

### Module 2: Dual Oxidase System (DUOX2/DUOXA2)
- **Statistics**: DUOX2 log2FC=4.67; DUOXA2 log2FC=2.89
- **Role**: Epithelial ROS production for antimicrobial defense; DUOXA2 is the maturation factor for DUOX2
- **Interaction type**: Direct physical interaction (DUOXA2 is the dedicated chaperone/maturation factor for DUOX2); regulatory interaction at the transcriptional level (both induced by inflammatory cytokines)
- **Evidence**: Direct input statistics; established biochemistry. This is a well-characterized direct functional partnership.

### Module 3: Calprotectin/Neutrophil Marker Complex (S100A8/S100P/LCN2)
- **Statistics**: S100A8 log2FC=3.80; S100P log2FC=1.77; LCN2 log2FC=2.67
- **Role**: Fecal calprotectin (S100A8/S100A9 heterodimer) is an established UC biomarker; LCN2 is co-released by neutrophils
- **Interaction type**: S100A8 forms a direct physical heterodimer with S100A9 (not in this dataset); S100A8 and LCN2 are co-expressed in neutrophils (co-expression); STRING evidence shows CDH3–S100A8 connection (confidence 0.892)
- **Evidence**: Direct input statistics; strong clinical biomarker literature. The S100A8–S100A9 heterodimer is a direct physical interaction, but S100A9 was not in this dataset; S100P–LCN2 relationship is co-expression within the neutrophil program.

### Module 4: Matrix Remodeling Module (MMP3/TIMP1/TNC/TGM2)
- **Statistics**: MMP3 log2FC=4.64; TIMP1 log2FC=1.97; TNC log2FC=2.58; TGM2 log2FC=1.91
- **Role**: ECM degradation, remodeling, and fibrosis in UC
- **Interaction type**: MMP3–TIMP1 is a direct physical enzyme-inhibitor interaction; TNC and TGM2 are ECM proteins (pathway co-membership in ECM organization); STRING evidence links TGM2 and TNC to ITGB1 (integrin signaling)
- **Evidence**: Direct input statistics; established biochemistry for MMP–TIMP binding; STRING network for ECM-integrin connections.

### Module 5: Bile Acid/Water Transport Loss (SLC51A/ABCB11/AQP7/AQP8)
- **Statistics**: SLC51A log2FC=-3.71; ABCB11 log2FC=-1.15; AQP7 log2FC=-2.32; AQP8 log2FC=-4.42
- **Role**: Loss of differentiated colonocyte transport functions
- **Interaction type**: SLC51A–SLC51B direct physical interaction (STRING confidence 0.999; SLC51B is the obligate beta subunit); AQP7–AQP8 are pathway co-members (water transport) and may form heterotetramers, though this is less well established
- **Evidence**: Direct input statistics; STRING interaction evidence; KEGG bile secretion pathway co-membership. SLC51A–SLC51B is a direct physical interaction; AQP7–AQP8 relationship is pathway co-membership with possible physical interaction (insufficient evidence for direct binding).

### Module 6: Negative Regulators of Inflammation (IL1RN/SOCS3/IRAK3)
- **Statistics**: IL1RN log2FC=2.88; SOCS3 log2FC=2.79; IRAK3 log2FC=1.78
- **Role**: Compensatory anti-inflammatory feedback
- **Interaction type**: Pathway co-membership in cytokine signaling regulation; SOCS3 is a direct negative regulator of JAK/STAT signaling; IRAK3 is a dominant-negative IRAK family member; IL1RN directly blocks IL-1 receptor
- **Evidence**: Direct input statistics; established regulatory biology. These represent regulatory interactions, not physical binding among themselves.

### Module 7: Epithelial Stress Markers (SLC6A14/TRIM29/PRRX1)
- **Statistics**: SLC6A14 log2FC=4.85; TRIM29 log2FC=2.83; PRRX1 log2FC=2.91
- **Role**: Epithelial stress response and possible metaplasia markers
- **Interaction type**: Co-expression within the stressed epithelial program; no established direct physical interaction among these three
- **Evidence**: Direct input statistics; literature association with inflammation and epithelial stress. Relationship is putative/co-expression.

### Module 8: Adaptive Immune Checkpoint (CTLA4/DAPP1/Immunoglobulin)
- **Statistics**: CTLA4 log2FC=2.62; DAPP1 log2FC=2.20; IGH cluster log2FC=1.89
- **Role**: T-cell regulation and B-cell/plasma cell infiltration
- **Interaction type**: CTLA4 and DAPP1 are in different immune cell lineages (T-cells vs B-cells); relationship is co-occurrence within the inflamed tissue microenvironment (indirect)
- **Evidence**: Direct input statistics; literature evidence for plasma cell infiltration in UC. The relationship is indirect/putative.

---

## 4. Validation Priorities

### Priority 1: Neutrophil Chemokine Axis as Therapeutic Target
- **Classification**: Therapeutic target
- **Rationale**: CXCL1/CXCL2/CXCL3 are among the most strongly upregulated genes and form a coherent neutrophil recruitment module. Blocking CXCR2 could reduce neutrophil influx in UC.
- **Current dataset evidence**: Strong upregulation of all three chemokines (log2FC 2.33–3.46, FDR < 2.6e-11); STRING evidence for CXCR2 connection.
- **External evidence**: CXCR2 antagonists have been explored in inflammatory diseases; IL-17 pathway is a validated UC target (though anti-IL-17 failed in Crohn's, highlighting pathway complexity). Literature supports neutrophil infiltration as a key UC feature.
- **Next step**: Functional validation in an independent UC cohort; measure CXCL1-3 protein levels in UC sera/biopsies; test CXCR2 blockade in a preclinical colitis model.
- **Status**: **Supported hypothesis** (strong input evidence, plausible mechanism, but no direct causal or therapeutic validation in this dataset).

### Priority 2: Differentiated Epithelial Function Loss as Biomarker Panel
- **Classification**: Biomarker
- **Rationale**: The coordinated downregulation of AQP8, SLC51A, HMGCS2, CYP2B6, and UGT2A3 may serve as a "loss of differentiation" signature reflecting disease severity or epithelial damage.
- **Current dataset evidence**: Multiple highly significant downregulated genes (FDR from 1.6e-13 to 1.1e-10).
- **External evidence**: AQP8 downregulation has been reported in UC; loss of colonocyte differentiation markers is a known feature of inflamed mucosa. BRINP3 downregulation has been specifically implicated in UC pathogenesis (PMID: 25171508).
- **Next step**: Validate the panel in an independent UC cohort; correlate with histologic disease activity; test whether the signature normalizes with successful therapy.
- **Status**: **Exploratory hypothesis** (input evidence strong, but external validation not performed).

### Priority 3: DUOX2/DUOXA2 ROS Production in Epithelial Injury
- **Classification**: Mechanistic hypothesis
- **Rationale**: DUOX2/DUOXA2 are strongly upregulated and may contribute to both antimicrobial defense and oxidative tissue damage.
- **Current dataset evidence**: DUOX2 log2FC=4.67, DUOXA2 log2FC=2.89, both among the top upregulated genes.
- **External evidence**: DUOX2 is induced by IFN-γ and bacterial products in intestinal epithelium; ROS production is implicated in IBD pathogenesis. However, DUOX2 deficiency can also cause very early-onset IBD, suggesting a dual role.
- **Next step**: Measure ROS production and DUOX2 protein in UC biopsies; test DUOX2 inhibition in epithelial cell models; examine genotype-phenotype correlations.
- **Status**: **Supported hypothesis** (strong input evidence; mechanistic plausibility; conflicting literature on protective vs pathogenic role).

### Priority 4: Cell-Composition Confounding Check
- **Classification**: Confounding or composition check
- **Rationale**: Many of the observed changes (S100A8, LCN2, CXCLs, immunoglobulin) could reflect increased neutrophil/plasma cell infiltration rather than transcriptional changes in epithelial cells. Conversely, AQP8/HMGCS2 loss could reflect epithelial cell depletion.
- **Current dataset evidence**: The pattern is consistent with composition changes, but no cell-type deconvolution was performed.
- **External evidence**: Single-cell RNA-seq studies of UC have shown both compositional shifts and cell-intrinsic transcriptional changes.
- **Next step**: Perform computational cell-type deconvolution (CIBERSORTx, MuSiC); validate with immunohistochemistry for key markers (S100A8 for neutrophils, AQP8 for colonocytes); consider single-cell validation.
- **Status**: **Exploratory hypothesis** (no direct evidence in this dataset; but this is a critical methodologic consideration).

### Priority 5: SLC6A14 and Amino Acid Transport in Epithelial Stress
- **Classification**: Mechanistic hypothesis / Biomarker
- **Rationale**: SLC6A14 is the most strongly upregulated gene (log2FC=4.85) and encodes a neutral/basic amino acid transporter implicated in intestinal inflammation.
- **Current dataset evidence**: Strongest single-gene signal in the dataset.
- **External evidence**: SLC6A14 has been implicated in Crohn's disease; it is induced by inflammatory cytokines and may regulate mTOR signaling and autophagy. Literature support exists but is not UC-specific.
- **Next step**: Validate in independent UC cohort; test SLC6A14 protein expression by IHC; examine functional role in intestinal epithelial cell models under inflammatory stress.
- **Status**: **Supported hypothesis** (very strong input evidence; moderate external support; functional role in UC requires validation).

---

## 5. Evidence Grounding

### Direct Evidence (from input dataset)
- All 100 genes with log2FC, P, FDR values; 100% pass FDR ≤ 0.01
- Direction counts: 40 upregulated, 60 downregulated
- This is the only direct statistical evidence for the cohort

### Pathway/Ontology Evidence
- GO: Fluid Transport, Water Transport, Carboxylic Acid Transport (retrieved for selected genes)
- KEGG: IL-17 signaling, Bile secretion, Rheumatoid arthritis (retrieved)
- These are contextual annotations, not enrichment statistics computed from this dataset

### Protein Interaction/Regulatory Evidence
- STRING: CXCL1/2/3–CXCR2; SLC51A–SLC51B (confidence 0.999); AQP7–AQP8; TGM2/TNC–ITGB1; CDH3–S100A8
- TRRUST: 31/100 genes have transcription factor regulatory records
- OmniPath: 45/100 genes with regulatory network records
- These are external interaction databases; not computed from this dataset

### Disease-Association Evidence
- GWAS: 100/100 selected genes have records (though this does not mean all are UC-associated)
- ClinVar: 90/100 genes with clinical variant records
- OpenTargets: 92/100 genes with disease association records
- Literature: BRINP3 specifically implicated in UC (PMID: 25171508); IRAK3 implicated in inflammatory regulation (PMID: 40918148)
- These records indicate disease relevance broadly, not UC-specific replication

### Expression/Tissue-Specific Evidence
- GTEx: 91/100 genes with expression records
- HPA: 85/100 genes with protein expression records
- These confirm the genes are expressed in relevant tissues but do not validate the UC-specific changes

### Genetic/Clinical Evidence
- GWAS records for all selected genes (contextual)
- No independent cohort statistics supplied

### Drug/Therapeutic Evidence
- ChEMBL: 40/100 genes with drug-target records (partial)
- ClinicalTrials: 51/100 genes with trial records
- These indicate druggability, not therapeutic efficacy in UC

### Literature Evidence
- 750 PubMed + 936 Europe PMC articles retrieved
- Key UC-relevant records: biomarker screening (PMID: 41029776); treatment response and environmental toxins (PMID: 38059894); BRINP3 in UC (PMID: 25171508)
- Literature supports the plausibility of the identified programs but does not constitute replication

### Independence Assessment
- The pathway annotations, interaction databases, and literature records draw on overlapping underlying publications and prediction models
- STRING interactions are partly derived from literature co-citation and experimental data—these are not fully independent evidence sources
- The uploaded statistics are the only truly independent direct evidence for this cohort
- **External statistical validation was not performed**; no independent cohort statistics were supplied

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue Cell-Composition Effects
- **Issue**: UC mucosa contains increased neutrophils, plasma cells, and myofibroblasts, and may have reduced epithelial content. Many observed changes (S100A8, LCN2, CXCL1-3, immunoglobulin) may reflect cellular infiltration rather than cell-intrinsic transcriptional changes. Similarly, AQP8, HMGCS2, and CYP2B6 loss may reflect epithelial cell depletion.
- **Investigation**: Computational deconvolution (CIBERSORTx, MuSiC, BayesPrism); immunohistochemistry for cell-type markers; single-cell RNA-seq validation.

### Limitation 2: Disease Severity and Treatment Exposure
- **Issue**: UC severity varies widely; treatment (5-ASA, steroids, biologics, immunosuppressants) profoundly affects mucosal transcription. The dataset does not specify disease activity or treatment status, which could confound the comparison.
- **Investigation**: Stratify by disease activity (Mayo score), treatment exposure, and disease extent; validate in treatment-naïve cohorts if possible.

### Limitation 3: Batch and Platform Effects
- **Issue**: The presence of probe IDs (PROBE_241592_PM_at, PROBE_227140_PM_at, PROBE_235105_PM_at) indicates an Affymetrix microarray platform. Batch effects, RNA quality differences, and platform-specific artifacts could influence results. The 43 duplicated genes/probes suggest probe redundancy.
- **Investigation**: Confirm with qPCR or RNA-seq; examine batch covariates; assess RNA integrity metrics.

### Limitation 4: Broad/Nonspecific Pathway Signals
- **Issue**: Many of the identified programs (neutrophil activation, ECM remodeling, metabolic changes) are common to various inflammatory conditions, not specific to UC. The KEGG "Rheumatoid arthritis" pathway reflects shared inflammatory mechanisms, not UC specificity.
- **Investigation**: Compare with other IBD subtypes (Crohn's disease) and other inflammatory conditions; identify UC-specific signatures.

### Limitation 5: Association Versus Causation
- **Issue**: This is a cross-sectional disease-state comparison. Upregulation of inflammatory genes could be a cause, consequence, or compensatory response to UC. The presence of negative regulators (IL1RN, SOCS3, IRAK3, CTLA4) suggests both pro- and anti-inflammatory programs are active simultaneously.
- **Investigation**: Longitudinal studies; genetic Mendelian randomization approaches; functional perturbation experiments in model systems.

---

## Summary

The transcriptomic data reveal a coherent UC mucosal signature characterized by **neutrophil-driven innate immune activation** (S100A8, LCN2, CXCL1-3, DUOX2), **loss of differentiated colonocyte functions** (AQP8, SLC51A, HMGCS2, CYP2B6), and **active tissue remodeling** (MMP3, TNC, TIMP1), alongside **compensatory anti-inflammatory signaling** (IL1RN, SOCS3, IRAK3). The strongest evidence supports neutrophil chemokine signaling and epithelial metabolic loss as core programs, with matrix remodeling as a downstream consequence. All 100 genes pass stringent FDR thresholds, providing robust direct evidence, but external cohort validation was not performed, and cell-composition confounding remains a critical unresolved issue that should be addressed before translational conclusions are drawn.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=65, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; some queries failed; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
